Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Cellectis S.A. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 78 | 70 | −8 |
| Shares | 16.2M | 15.4M | −824.9K (−5.1%) |
| Value | $250.6M | $194.1M | −$56.6M (−22.6%) |
New holders (5)
Institutions that held Cellectis S.A. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 170,286 | $2.21M | 0.01% |
| Woodline Partners LP | 93,132 | $1.17M | 0.02% |
| Deutsche Bank AG | 3,300 | $42.0K | 0.00% |
| Gerber Kawasaki Wealth & Investment Management | 5 | $0 | 0.00% |
| Kowal Investment Group, LLC | 2 | $0 | 0.00% |
Sold out (13)
Institutions that held Cellectis S.A. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Envestnet Asset Management Inc | 63,766 | $986.0K |
| Two Sigma Investments, LP | 22,354 | $346.0K |
| Capital Asset Advisory Services LLC | 21,745 | $336.0K |
| Vident Investment Advisory, LLC | 14,268 | $221.0K |
| Ameriprise Financial Inc | 11,822 | $184.0K |
| Geneos Wealth Management Inc. | 7,470 | $113.0K |
| Acadian Asset Management LLC | 3,227 | $50.0K |
| Proequities, Inc. | 2,724 | $42.0K |
| Arkadios Wealth Advisors | 489 | $7.00K |
| Advisory Services Network, LLC | 100 | $2.00K |
| Patriot Financial Group Insurance Agency, LLC | 90 | $1.00K |
| Fieldpoint Private Securities, LLC | 55 | $1.00K |
| First Horizon Advisors, Inc. | 33 | $0 |